The biggest challenge that resveratrol researchers are currently
facing is its poor in vivo bioavailability. In mammals, resveratrol is
metabolized by the intestine and liver, mainly into glucuronides
and sulfonates [78–83]. Resveratrol is very quickly metabolized,
usually within 30–60 min after administration, although by changing
some variables in how the drug is given, the peak plasma concentration
can be delayed slightly. Because it is so quickly
metabolized, it is difficult to use systemically as a drug treatment
since it disappears from the plasma in such a short time [78]. There
are several ways that researchers are trying to combat this problem
to make resveratrol treatment viable against skin cancers
and diseases.